|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, an obvious negative correlation between miR-376c-3p and ARID2 mRNA expression in HCC tissues was confirmed.
|
30519319 |
2018 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent genomic studies have identified frequent mutations of ARID2, a component of the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex, in hepatocellular carcinoma, but it is not still understood how ARID2 exhibits tumor suppressor activities.
|
28238438 |
2017 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
While ICC and HCC share recurrently mutated genes, including TP53, ARID1A, and ARID2, mitotic checkpoint anomalies distinguish the C1 subtype with key drivers PLK1 and ECT2, whereas the C2 subtype is linked to obesity, T cell infiltration, and bile acid metabolism.
|
28648284 |
2017 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Functionally, ARID2 abrogated HBx-enhanced migration and proliferation of hepatoma cells, whereas depletion of ATOH1 enhanced tumorigenecity of HCC cells.
|
28498550 |
2017 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Notably, alterations of ARID2 expression abrogated the effects of miR‑155 on HCC cell proliferation, cell cycle and apoptosis.
|
27035278 |
2016 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings highlight the potential role of ARID2 as a tumor growth suppressor in HCC.
|
27351279 |
2016 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In vitro, miR-208-3p down-regulation and ARID2 over-expression elicited similar inhibitory effects on HCC cell proliferation and invasion.
|
26169693 |
2015 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
AT-rich interactive domain 2 (ARID2), catenin (cadherin-associated protein), beta 1, 88kDa (β-catenin), tumor protein 53 (p53), and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (p110α) mutations are implicated in hepatocellular carcinoma (HCC); and previous work has contributed to thorough molecular characterization of these events.
|
25701229 |
2015 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, by taking account of genomic mutations causing transcriptional aberrations, we could improve the sensitivity of deleterious mutation detection in known cancer driver genes (TP53, AXIN1, ARID2, RPS6KA3), and identified recurrent disruptions in putative cancer driver genes such as HNF4A, CPS1, TSC1 and THRAP3 in HCCs.
|
25526364 |
2014 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
High-throughput short-read sequencing of exomes and whole cancer genomes in multiple human hepatocellular carcinoma (HCC) cohorts confirmed previously identified frequently mutated somatic genes, such as TP53, CTNNB1 and AXIN1, and identified several novel genes with moderate mutation frequencies, including ARID1A, ARID2, MLL, MLL2, MLL3, MLL4, IRF2, ATM, CDKN2A, FGF19, PIK3CA, RPS6KA3, JAK1, KEAP1, NFE2L2, C16orf62, LEPR, RAC2, and IL6ST.
|
24379610 |
2013 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.
|
22634756 |
2012 |
|
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Notably, 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype.
|
21822264 |
2011 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we summarize the current knowledge about the relevance of ARID2 in HCC and the implication in future patient care.
|
22095441 |
2011 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Notably, 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype.
|
21822264 |
2011 |
|
Liver carcinoma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Coffin-Siris syndrome
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Previously reported ARID2 mutations manifested clinically with a CSS-like phenotype including intellectual disability, coarsened facial features, fifth toenail hypoplasia, and other recognizable dysmorphisms.
|
30838730 |
2019 |
|
Coffin-Siris syndrome
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Here we describe 7 unrelated individuals, 2 with deletions of the ARID2 region and 5 with de novo truncating mutations in the ARID2 gene.Similarities to CSS are evident.
|
29698805 |
2019 |
|
Coffin-Siris syndrome
|
0.330 |
GermlineCausalMutation
|
disease |
ORPHANET |
Heterozygosity for ARID2 loss-of-function mutations in individuals with a Coffin-Siris syndrome-like phenotype.
|
28124119 |
2017 |
|
Coffin-Siris syndrome
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Heterozygosity for ARID2 loss-of-function mutations in individuals with a Coffin-Siris syndrome-like phenotype.
|
28124119 |
2017 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Intellectual Disability
|
0.160 |
GeneticVariation
|
group |
BEFREE |
Previously reported ARID2 mutations manifested clinically with a CSS-like phenotype including intellectual disability, coarsened facial features, fifth toenail hypoplasia, and other recognizable dysmorphisms.
|
30838730 |
2019 |
|
Intellectual Disability
|
0.160 |
GeneticVariation
|
group |
BEFREE |
Extending the clinical and genetic spectrum of ARID2 related intellectual disability. A case series of 7 patients.
|
29698805 |
2019 |
|
Intellectual Disability
|
0.160 |
Biomarker
|
group |
BEFREE |
The phenotype confirmed the major features of the recently described ARID2-related intellectual disability syndrome.
|
28884947 |
2017 |
|
Intellectual Disability
|
0.160 |
GeneticVariation
|
group |
BEFREE |
In 2015, mutations in the ARID2 gene were associated with intellectual disability.
|
28124119 |
2017 |